Results 111 to 120 of about 28,302,100 (317)
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura +19 more
wiley +1 more source
Protocol for a health technology assessment of screening for abdominal aortic aneurysm in men
Following a request from the National Screening Advisory Committee (NSAC), HIQA has commenced work on a health technology assessment (HTA) of screening for abdominal aortic aneurysm (AAA) in men in Ireland.
Health Information and Quality Authority (HIQA)
core
Pair‐wise comparison of the CellSearch and FETCH enrichment technologies for circulating tumor cells (CTCs) from metastatic breast, prostate, and small cell lung cancer patients shows an increased capture of CTCs using FETCH enrichment. The clinical implementation of circulating tumor cells (CTCs) as a predictive tool for therapy efficacy in the ...
Michiel Stevens +6 more
wiley +1 more source
Office of Technology Assessment List of Publications, January 1993
A catalog of Office of Technology Assessment (OTA) documents published through ...
Office of Technology Assessment
core
Matched spatial transcriptomics and single‐nuclei RNA‐seq were generated for anaplastic and BRAFV600E papillary thyroid cancers revealing generic and tumor‐specific states occurring in cancer cells and in the tumor microenvironment. In this context, cancer dedifferentiation mirrored organoid maturation through ordered thyroid marker gain/loss ...
Adrien Tourneur +11 more
wiley +1 more source
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington +10 more
wiley +1 more source
Protocol for a health technology assessment of extending BowelScreen to those aged 50 to 54 years
Following a request from the National Screening Advisory Committee (NSAC), HIQA has commenced work on a health technology assessment (HTA) of extending Ireland’s national colorectal cancer screening programme, BowelScreen, to those aged 50 to 54 years ...
Health Information and Quality Authority (HIQA)
core
Office of Technology Assessment List of Publications, September 1985
A catalog of Office of Technology Assessment (OTA) documents published through ...
Office of Technology Assessment
core
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq +8 more
wiley +1 more source
Office of Technology Assessment List of Publications, April 1980
A catalog of Office of Technology Assessment (OTA) documents published through ...
Office of Technology Assessment
core

